2018 · 2017 · 2016 · 2015 · 2014 · 2013 ·
  • The World Congress of the “International Cartilage Repair Society (ICRS)” is one of the most important events in the field of cartilage attracting scientists, orthopaedic specialists and industry. Geistlich Surgery was represented in different forums at this year’s ICRS congress in Chicago, thus positioning itself successfully as collagen experts in the field of orthopaedics.

  • Geistlich Pharma North America successfully introduced the collagen matrix, Geistlich Mucograft® Seal, onto the North American market at the 30th Congress of the Academy of Osseointegration in San Francisco from 12th – 14th March 2015. With about 2,500 participants the annual congress this year was received particularly well.

  • Today, Friday, Geistlich Pharma was to collect the 2014 IHZ (Chamber of Industry and Commerce of Central Switzerland) Innovation Award. The pioneering products, Geistlich Mucograft® and Geistlich Mucograft® Seal, were chosen as winners out of 23 projects.

  • Geistlich Pharma establishes its ninth affiliate, Geistlich Pharma Australia PTY Ltd. From 1 January 2015, Geistlich Pharma will be serving the Australian and New Zealand market directly from Sydney. The distributor up to now, Henry Schein, will remain the partner for general dental practitioners.

  • Between 19 and 27 September, important congresses on regenerative dental medicine were held in the three metropolises of San Francisco, Shanghai and Rome. Geistlich managed the balancing act between three continents and between scientificity and practical relevance.

  • According to a court settlement of 12 May 2014, the South Korean company Osstem must refrain from any distribution of dental products under the name B-Oss and destroy all existing products bearing this name. The name and the packaging of this product were similar to that of the long-standing market leader Geistlich Bio-Oss®.

  • Geistlich Pharma wins the 2014 prize for innovation from the Chamber of Industry and Commerce of Central Switzerland (IHZ). The IHZ rated the products Geistlich Mucograft® and Geistlich Mucograft® Seal as an outstanding achievement.

  • At its meeting on 26 August 2014, the Board of Directors of Geistlich Pharma AG reconstituted itself. Dr Andreas Geistlich is the new President of the Board of Directors.

  • Colleagues and management mourn the passing of Dr. Peter Geistlich; over many years he decisively shaped the development of the family company which is over 160 years old, enabling it to enter regenerative medicine. The obituary recalls and honours Peter Geistlich, scientist, entrepreneur and unique human being. 

  • The new website of Geistlich Pharma AG has been live since today. With the re-launch, the information content has been tailored even more specifically to the information requirements of specialist clinic personnel and their patients. In addition to product information, therapy concepts with case studies and easy-to-understand video material are also available. Furthermore, the website has a fresher design and a more user-friendly web architecture.

Dr. Mirjam Kessler
Director Corporate Communications